RecruitingPHASE1, PHASE2NCT04443010

Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

Studying Giant cell glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Philogen S.p.A.
Principal Investigator
Tobias Weiss, PhD, MD
Universitatspital Zurich - Klinik fur Neurologie & Hirntumorzentrum
Intervention
Onfekafusp alfa(drug)
Enrollment
226 enrolled
Eligibility
18 years · All sexes
Timeline
20212026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04443010 on ClinicalTrials.gov

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Giant cell glioblastoma

← Back to all trials